GSK plc logo

GSK plc

TickerGSK.LVenueLSESectorHealthcarePrimary listingBeta0.29
1,855pGBX-0.40%
FinScore57

GSK plc is a United Kingdom-based company in the Healthcare sector with a market capitalisation of $99.4B. Its FinScore is 57/100; its highest-scoring layer is Quality (78) and its lowest is Growth (34). The shares trade at 15.5x trailing earnings and are up 2% year to date.

Market cap
$99.4B
P/E (TTM)
15.5x
Dividend yield (TTM)
3.65%
ROE
28.3%

Share price performance

Loading chart…

About GSK plc

www.gsk.com

GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.

Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
HQ
United Kingdom
Fiscal year-end
December
Trading currency
GBP
Reporting currency
GBP
Fundamentals updated
82 days ago
Market
Market cap
$99.4B
Shares outstanding
4.0B
P/E (TTM)
15.5x
Dividend yield (TTM)
3.65%
Beta (issuer)
0.29
Revenue (latest FY)
£32.7B

Revenue breakdown

FY 2022£9.0B
  • Sub Total
    100.0%£9.0B

FinScore

As of 2026-10-19
Overall57
Quality78
Growth34
Value54
Momentum67
Relative Strength42

Snapshot

Ownership

As of 2026-03-31
Institutional
5.5%
Insider
—
Free float
96.9%
Top-5 institutional holders
7.1%
Shares outstanding
4.0B
Sign up to see the top holders

Sign up or log in to see Analysis

Analysis for GSK plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Financials

Financials for GSK plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Estimates

Estimates for GSK plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Peers

Peers for GSK plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Valuation

Valuation for GSK plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see News

News for GSK plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.